{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:47:42Z","timestamp":1794440862744,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070211"],"award-info":[{"award-number":["82070211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670152"],"award-info":[{"award-number":["81670152"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070217"],"award-info":[{"award-number":["82070217"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873427"],"award-info":[{"award-number":["81873427"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770211"],"award-info":[{"award-number":["81770211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830008"],"award-info":[{"award-number":["81830008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81630006"],"award-info":[{"award-number":["81630006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Top-notch Talent Cultivation Program of Hubei Province"},{"name":"CHEN XIAO-PING Foundation for the Development of Science and Technology of Hubei Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>TP53<\/jats:italic>\n                    gene alteration confers inferior prognosis in refractory\/relapse aggressive B-cell non-Hodgkin lymphoma (r\/r B-NHL). From September 2016 to September 2020, 257 r\/r B-NHL patients were assessed for eligibility for two trials in our center, assessing anti-CD19 and anti-CD22 chimeric antigen receptor (CAR19\/22) T-cell cocktail treatment alone or in combination with autologous stem cell transplantation (ASCT).\n                    <jats:italic>TP53<\/jats:italic>\n                    alterations were screened in 123 enrolled patients and confirmed in 60. CAR19\/22 T-cell administration resulted in best objective (ORR) and complete (CRR) response rate of 87.1% and 45.2% in patients with\n                    <jats:italic>TP53<\/jats:italic>\n                    alterations, respectively. Following a median follow-up of 16.7 months, median progression-free survival (PFS) was 14.8 months, and 24-month overall survival (OS) was estimated at 56.3%. Comparable ORR, PFS, and OS were determined in individuals with or without\n                    <jats:italic>TP53<\/jats:italic>\n                    alterations, and in individuals at different risk levels based on functional stratification of\n                    <jats:italic>TP53<\/jats:italic>\n                    alterations. CAR19\/22 T-cell treatment in combination with ASCT resulted in higher ORR, CRR, PFS, and OS, but reduced occurrence of severe CRS in this patient population, even in individuals showing stable or progressive disease before transplantation. The best ORR and CRR in patients with\n                    <jats:italic>TP53<\/jats:italic>\n                    alterations were 92.9% and 82.1%, respectively. Following a median follow-up of 21.2 months, 24-month PFS and OS rates in patients with\n                    <jats:italic>TP53<\/jats:italic>\n                    alterations were estimated at 77.5% and 89.3%, respectively. In multivariable analysis, this combination strategy predicted improved OS. In conclusion, CAR19\/22 T-cell therapy is efficacious in r\/r aggressive B-NHL with\n                    <jats:italic>TP53<\/jats:italic>\n                    alterations. Combining CAR-T cell administration with ASCT further improves long-term outcome of these patients.\n                  <\/jats:p>","DOI":"10.1038\/s41392-022-00924-0","type":"journal-article","created":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T20:02:23Z","timestamp":1649620943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-9368","authenticated-orcid":false,"given":"Jia","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekai","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fankai","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangkun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongcun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-9230","authenticated-orcid":false,"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-3232","authenticated-orcid":false,"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"924_CR1","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood 130, 1800\u20131808 (2017).","journal-title":"Blood"},{"key":"924_CR2","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 4184\u20134190 (2010).","journal-title":"J. Clin. Oncol."},{"key":"924_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"924_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"924_CR5","first-page":"40","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson, C. et al. Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel). Blood 136, 40\u201342 (2020).","journal-title":"Blood"},{"key":"924_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2020-134449","volume":"136","author":"SS Neelapu","year":"2020","unstructured":"Neelapu, S. S. et al. Interim analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL). Blood 136, 49\u201349 (2020).","journal-title":"Blood"},{"key":"924_CR7","doi-asserted-by":"crossref","unstructured":"Chen, L. et al. CAR T-cell therapy for a relapsed\/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome. J. Immunother. Cancer 8, e000364 (2020).","DOI":"10.1136\/jitc-2019-000364"},{"key":"924_CR8","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","volume":"4","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 4, 2325\u20132338 (2020).","journal-title":"Blood Adv."},{"key":"924_CR9","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","volume":"34","author":"J Pan","year":"2020","unstructured":"Pan, J. et al. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children. Leukemia 34, 3382\u20133387 (2020).","journal-title":"Leukemia"},{"key":"924_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine, A. J. p53: 800 million years of evolution and 40 years of discovery. Nat. Rev. Cancer 20, 471\u2013480 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"924_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"AJ Levine","year":"2009","unstructured":"Levine, A. J. & Oren, M. The first 30 years of p53: Growing ever more complex. Nat. Rev. Cancer 9, 749\u2013758 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"924_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden, K. H. & Prives, C. Blinded by the light: The growing complexity of p53. Cell 137, 413\u2013431 (2009).","journal-title":"Cell"},{"key":"924_CR13","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette, Z. Y. et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 120, 3986\u20133996 (2012).","journal-title":"Blood"},{"key":"924_CR14","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/ijc.30838","volume":"141","author":"T Zenz","year":"2017","unstructured":"Zenz, T. et al. TP53 mutation and survival in aggressive B cell lymphoma. Int. J. Cancer 141, 1381\u20131388 (2017).","journal-title":"Int. J. Cancer"},{"key":"924_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830\u2013837 (2011).","journal-title":"Nat. Genet."},{"key":"924_CR16","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","volume":"22","author":"RD Morin","year":"2016","unstructured":"Morin, R. D. et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin. Cancer Res. 22, 2290\u20132300 (2016).","journal-title":"Clin. Cancer Res."},{"key":"924_CR17","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","volume":"4","author":"CK Rushton","year":"2020","unstructured":"Rushton, C. K. et al. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv. 4, 2886\u20132898 (2020).","journal-title":"Blood Adv."},{"key":"924_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2017.75.5215","volume":"36","author":"M Qian","year":"2018","unstructured":"Qian, M. et al. TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J. Clin. Oncol. 36, 591\u2013599 (2018).","journal-title":"J. Clin. Oncol."},{"key":"924_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong, T. N. et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518, 552\u2013555 (2015).","journal-title":"Nature"},{"key":"924_CR20","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","volume":"119","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette, Z. Y. et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 119, 3668\u20133683 (2012).","journal-title":"Blood"},{"key":"924_CR21","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","volume":"16","author":"Y Miao","year":"2019","unstructured":"Miao, Y. et al. Genetic alterations and their clinical implications in DLBCL. Nat. Rev. Clin. Oncol. 16, 634\u2013652 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"924_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1182\/asheducation-2018.1.69","volume":"2018","author":"A Rosenthal","year":"2018","unstructured":"Rosenthal, A. & Rimsza, L. Genomics of aggressive B-cell lymphoma. Hematol. Am. Soc. Hematol. Educ. Program 2018, 69\u201374 (2018).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"924_CR23","doi-asserted-by":"publisher","first-page":"83294","DOI":"10.18632\/oncotarget.13065","volume":"7","author":"Y Cao","year":"2016","unstructured":"Cao, Y. et al. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. Oncotarget 7, 83294\u201383307 (2016).","journal-title":"Oncotarget"},{"key":"924_CR24","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S1470-2045(17)30444-8","volume":"18","author":"A Chiappella","year":"2017","unstructured":"Chiappella, A. et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 18, 1076\u20131088 (2017).","journal-title":"Lancet Oncol."},{"key":"924_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/hon.2438_12","volume":"35","author":"A Chiappella","year":"2017","unstructured":"Chiappella, A. et al. Biodlcl04: The prognostic role of cell of origin profile, Myc, Bcl2, and Tp53 in untreated poor-risk diffuse large B-cell lymphoma. Hematol. Oncol. 35, 157\u2013158 (2017).","journal-title":"Hematol. Oncol."},{"key":"924_CR26","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund, C. W. et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 130, 1903\u20131910 (2017).","journal-title":"Blood"},{"key":"924_CR27","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","volume":"105","author":"S Ferrero","year":"2020","unstructured":"Ferrero, S. et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study. Haematologica 105, 1604\u20131612 (2020).","journal-title":"Haematologica"},{"key":"924_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","volume":"126","author":"MH Delfau-Larue","year":"2015","unstructured":"Delfau-Larue, M. H. et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood 126, 604\u2013611 (2015).","journal-title":"Blood"},{"key":"924_CR29","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.3324\/haematol.2018.194399","volume":"103","author":"CW Eskelund","year":"2018","unstructured":"Eskelund, C. W. et al. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. Haematologica 103, e541\u2013e543 (2018).","journal-title":"Haematologica"},{"key":"924_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2020.11.013","volume":"39","author":"S Chen","year":"2021","unstructured":"Chen, S. et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell 39, 225\u2013239 e228 (2021).","journal-title":"Cancer Cell"},{"key":"924_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","volume":"135","author":"N Wang","year":"2020","unstructured":"Wang, N. et al. Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood 135, 17\u201327 (2020).","journal-title":"Blood"},{"key":"924_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.176","volume":"10","author":"J Wei","year":"2020","unstructured":"Wei, J. et al. Long-term outcomes of relapsed\/refractory double-hit lymphoma (r\/r DHL) treated with CD19\/22 CAR T-cell cocktail therapy. Clin. Transl. Med. 10, e176 (2020).","journal-title":"Clin. Transl. Med."},{"key":"924_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01800-6","volume":"7","author":"M Kazantseva","year":"2017","unstructured":"Kazantseva, M. et al. Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression. Sci. Rep. 7, 1566 (2017).","journal-title":"Sci. Rep."},{"key":"924_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/bjh.13562","volume":"171","author":"AG Evans","year":"2015","unstructured":"Evans, A. G. et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br. J. Haematol. 171, 205\u2013209 (2015).","journal-title":"Br. J. Haematol."},{"key":"924_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"924_CR36","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S Cordoba","year":"2021","unstructured":"Cordoba, S. et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat. Med. 27, 1797\u20131805 (2021).","journal-title":"Nat. Med."},{"key":"924_CR37","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J. Y. et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat. Med. 27, 1419\u20131431 (2021).","journal-title":"Nat. Med."},{"key":"924_CR38","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233\u20135239 (2008).","journal-title":"J. Clin. Oncol."},{"key":"924_CR39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood.2018883421","volume":"134","author":"CS Sauter","year":"2019","unstructured":"Sauter, C. S. et al. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood 134, 626\u2013635 (2019).","journal-title":"Blood"},{"key":"924_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2217\/imt.10.20","volume":"2","author":"MN Bouchlaka","year":"2010","unstructured":"Bouchlaka, M. N., Redelman, D. & Murphy, W. J. Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. Immunotherapy 2, 399\u2013418 (2010).","journal-title":"Immunotherapy"},{"key":"924_CR41","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127, 2980\u20132990 (2016).","journal-title":"Blood"},{"key":"924_CR42","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907\u2013912 (2005).","journal-title":"J. Exp. Med."},{"key":"924_CR43","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.4049\/jimmunol.163.10.5211","volume":"163","author":"J Shimizu","year":"1999","unstructured":"Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211\u20135218 (1999).","journal-title":"J. Immunol."},{"key":"924_CR44","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1084\/jem.20041130","volume":"200","author":"MJ Turk","year":"2004","unstructured":"Turk, M. J. et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200, 771\u2013782 (2004).","journal-title":"J. Exp. Med."},{"key":"924_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.coi.2005.02.002","volume":"17","author":"C Wrzesinski","year":"2005","unstructured":"Wrzesinski, C. & Restifo, N. P. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr. Opin. Immunol. 17, 195\u2013201 (2005).","journal-title":"Curr. Opin. Immunol."},{"key":"924_CR46","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"924_CR47","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"924_CR48","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ajh.25951","volume":"95","author":"P Sesques","year":"2020","unstructured":"Sesques, P. et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center. Am. J. Hematol. 95, 1324\u20131333 (2020).","journal-title":"Am. J. Hematol."},{"key":"924_CR49","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.1200\/JCO.2019.37.15_suppl.7517","volume":"37","author":"JY Spiegel","year":"2019","unstructured":"Spiegel, J. Y. et al. Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the U.S. Lymphoma CAR-T Consortium. J. Clin. Oncol. 37, 7517\u20137517 (2019).","journal-title":"J. Clin. Oncol."},{"key":"924_CR50","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1182\/blood-2021-148078","volume":"138","author":"C Jacobson","year":"2021","unstructured":"Jacobson, C. et al. Long-term (\u22654 year and \u22655 year) overall survival (OS) By 12- and 24-month event-free survival (EFS): An updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma (LBCL). Blood 138, 1764\u20131764 (2021).","journal-title":"Blood"},{"key":"924_CR51","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino, L. et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 4, 5607\u20135615 (2020).","journal-title":"Blood Adv."},{"key":"924_CR52","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T consortium. J. Clin. Oncol. 38, 3119\u20133128 (2020).","journal-title":"J. Clin. Oncol."},{"key":"924_CR53","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jmoldx.2020.02.007","volume":"22","author":"Y Lou","year":"2020","unstructured":"Lou, Y. et al. Detection and quantification of chimeric antigen receptor transgene copy number by droplet digital PCR versus real-time PCR. J. Mol. Diagn. 22, 699\u2013707 (2020).","journal-title":"J. Mol. Diagn."},{"key":"924_CR54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/cr.2017.146","volume":"28","author":"L Huang","year":"2018","unstructured":"Huang, L. et al. Integrated genomic analysis identifies deregulated JAK\/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 28, 172\u2013186 (2018).","journal-title":"Cell Res."},{"key":"924_CR55","doi-asserted-by":"crossref","unstructured":"Robles, A. I., Jen, J. & Harris, C. C. Clinical outcomes of TP53 mutations in cancers. Cold Spring Harb. Perspect. Med. 6, a026294 (2016).","DOI":"10.1101\/cshperspect.a026294"},{"key":"924_CR56","doi-asserted-by":"crossref","unstructured":"Hainaut, P. & Pfeifer, G. P. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb. Perspect. Med. 6, a026179 (2016).","DOI":"10.1101\/cshperspect.a026179"},{"key":"924_CR57","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1158\/2159-8290.CD-18-1391","volume":"9","author":"E Loizou","year":"2019","unstructured":"Loizou, E. et al. A gain-of-function p53-mutant oncogene promotes cell fate plasticity and myeloid leukemia through the pluripotency factor FOXH1. Cancer Discov. 9, 962\u2013979 (2019).","journal-title":"Cancer Discov."},{"key":"924_CR58","doi-asserted-by":"publisher","first-page":"a001107","DOI":"10.1101\/cshperspect.a001107","volume":"2","author":"M Oren","year":"2010","unstructured":"Oren, M. & Rotter, V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2, a001107 (2010).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"924_CR59","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1056\/NEJMoa073770","volume":"357","author":"ML Poeta","year":"2007","unstructured":"Poeta, M. L. et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 357, 2552\u20132561 (2007).","journal-title":"N. Engl. J. Med."},{"key":"924_CR60","doi-asserted-by":"crossref","unstructured":"Dutta, S. et al. Functional classification of TP53 mutations in acute myeloid leukemia. Cancers 12, 637 (2020).","DOI":"10.3390\/cancers12030637"},{"key":"924_CR61","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1158\/0008-5472.CAN-14-2735","volume":"75","author":"DM Neskey","year":"2015","unstructured":"Neskey, D. M. et al. Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res. 75, 1527\u20131536 (2015).","journal-title":"Cancer Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00924-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T03:37:45Z","timestamp":1675222665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00924-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1038\/s41392-022-00924-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"5 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}